ArticleFrontiers in immunology2025
GATA2 deficiency in an adult with alveolar proteinosis, infections, lymphadenopathy with granulomatosis, and immune deficiency: case report.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GATA2 protein is an important hematopoietic transcription factor. GATA2 deficiency, caused by heterozygous mutation of GATA2, includes a group of diseases presented with monocytopenia, cellular immunodeficiency with marked susceptibility to infection (mycobacterial, fungal, and viral), myelodysplasia (MDS), leukemic transformation, vessel abnormalities, and deafness. Most data are available in case reports. The challenge is to increase the awareness about GATA2 deficiency and to find the best treatment protocol for the patient. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment available. However, it is also associated with significant treatment-related morbidity and mortality. Therefore, determining the appropriate timing of allo-HSCT is critical. We present the case of a young adult man with severe lung alveolar proteinosis, granulomatous disease, infections, and autoimmune complications present before we confirm GATA2 as a newly described mutation. The main sign that led to the suspicion of GATA2 deficiency was prolonged monocytopenia and absence of monocyte in peripheral blood and bone marrow along with recurrent infections and alveolar proteinosis. The exact and early diagnosis of this disease is crucial. The late stage of the disease is associated with increased mortality and severe complications that contraindicate bone marrow transplantation or worsen survival. The clinical implication of this article is to improve awareness about the different clinical forms of GATA2 deficiency and the new mutations described in this field. Our aim is to share real-life experiences with disease development and treatment during the lifetime of a young patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.